All In Biotech

Drug Trial Radar · NCT07884877

PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer

A Prospective Phase II Study of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) Combined With Immunotherapy in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Oct 2028

Study completion Oct 2030

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma (liver cancer). It will also learn about the safety of this combination. The main questions it aims to answer are: * What percentage of participants are alive without cancer progression 12 months after starting PULSAR? * What medical problems do participants have after PULSAR with immunotherapy? There is no comparison group. Results will be compared with published results of immunotherapy alone. Participants will: * Continue their usual immunotherapy * Receive 2 to 3 PULSAR sessions, 3 to 4 weeks apart, with the plan adjusted before each session * Give blood samples and fill out symptom questionnaires * Have checkups and scans for up to 3 years

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Radiotherapy-Induced Immune Priming
  • Immunotherapy

Interventions

  • PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy)Radiation

    Stereotactic radiotherapy (photon or proton), 8-12 Gy per pulse, 2-3 pulses at 3- to 4-week intervals, delivered between immunotherapy cycles. CT-based adaptive re-planning is performed before each pulse, with target volume reduced according to tumor response.

  • Immune checkpoint inhibitor-based therapyDrug

    Standard-of-care immune checkpoint inhibitor-based systemic therapy chosen by the treating physician. Not provided by the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-Month Progression-Free Survival RateTime frame: 12 months from start of radiotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung medical center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.